Skip to main content
Premium Trial:

Request an Annual Quote

Sequenom's Shares Soar on Launch of Fetal Sex Determination Test

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Shares of Sequenom were up 14 percent in mid-afternoon trade on the Nasdaq after the firm announced earlier today the launch of its SensiGene Fetal (XY) test through its CLIA lab, the Sequenom Center for Molecular Medicine.

The new SensiGene test is a non-invasive assay that detects circulating cell-free fetal DNA in maternal blood. It interrogates male specific targets on the Y chromosome and runs on Sequenom's MassArray system.

Sequenom said that a validation study showed that the test had 97.9 percent sensitivity and 100 percent specificity.

The firm's shares were up $.63 at $5.15 in Tuesday afternoon trade on the Nasdaq.

Two weeks ago, Sequenom's shares spiked on the launch of its SensiGene Fetal RHD Genotyping test.

Sequenom's shares had not traded above $5 since late September 2009. At that time, the firm had announced the dismissal of its CEO and other top executives in the wake of an investigation into the mishandling of test data on its Down Syndrome test.

The Scan

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.

Effectiveness May Decline, Data From Israel Suggests

The New York Times reports that new Israeli data suggests a decline in Pfizer-BioNTech SARS-CoV-2 vaccine effectiveness against Delta variant infection, though protection against severe disease remains high.

To See Future Risk

Slate looks into the use of polygenic risk scores in embryo screening.

PLOS Papers on Methicillin-Resistant Staphylococcus, Bone Marrow Smear Sequencing, More

In PLOS this week: genomic analysis of methicillin-resistant Staphylococcus pseudintermedius, archived bone marrow sequencing, and more.